Serial Cell-free DNA Assessments in Preclinical Models

Ariana Rostami; Caberry Yu; Scott V Bratman

doi:10.1016/j.xpro.2020.100145

Serial Cell-free DNA Assessments in Preclinical Models

STAR Protoc. 2020 Oct 20;1(3):100145. doi: 10.1016/j.xpro.2020.100145. eCollection 2020 Dec 18.

Authors

Ariana Rostami^{1

2}, Caberry Yu¹, Scott V Bratman^{1

2

3}

Affiliations

¹ Princess Margaret Cancer Center, University Health Network, 101 College Street, Toronto, ON M5G 1L7, Canada.
² Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, ON M5G 1L7, Canada.
³ Department of Radiation Oncology, University of Toronto, 149 College Street, Toronto, ON M5T 1P5, Canada.

Abstract

Studying circulating cell-free DNA (cfDNA) release within preclinical model systems provides opportunities to investigate the mechanisms and kinetics underlying this process under various conditions. We present a detailed protocol for longitudinal evaluation of cfDNA release through (1) seeding of cancer cell lines and establishment of xenograft tumors, (2) treatment of cancer cells and xenograft tumors, (3) serial collection of cell line media and xenograft blood, and (4) processing and isolation of cfDNA for (5) quantification of cfDNA by quantitative PCR. For complete details on the use and execution of this protocol please refer to Rostami et al. (2020).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cell Line, Tumor
Cell-Free Nucleic Acids / analysis*
Cell-Free Nucleic Acids / genetics
Culture Media / analysis
Humans
Mice
Real-Time Polymerase Chain Reaction / methods*
Xenograft Model Antitumor Assays / methods

Substances

Cell-Free Nucleic Acids
Culture Media